Home > Boards > US Listed > Biotechs > Stemline Therapeutics (STML)

SL-401 receives Orphan Drug designation in BPDCN. A

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DonShimoda Member Profile
 
Followed By 22
Posts 758
Boards Moderated 0
Alias Born 11/10/09
160x600 placeholder
Stemline Therapeutics Highlights Recent Clinical and Regulatory Developments and Details Upcoming Milestones following its An... GlobeNewswire Inc. - 7/8/2019 5:50:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:18:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:17:55 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:17:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:17:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:16:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:16:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:16:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:15:29 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 6/28/2019 5:11:12 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/28/2019 4:32:51 PM
Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune ... GlobeNewswire Inc. - 6/17/2019 7:30:00 AM
Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp) Clinical Presentations at EHA Congress June 13-15 GlobeNewswire Inc. - 6/13/2019 7:30:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 6/11/2019 5:03:08 PM
Notice of Exempt Solicitation. Definitive Material. (px14a6g) Edgar (US Regulatory) - 6/11/2019 3:44:59 PM
Stemline Therapeutics Announces ASCO Presentation of ELZONRIS Phase 2 Clinical Data in CMML and MF; Provides Next Steps for C... GlobeNewswire Inc. - 6/3/2019 7:30:00 AM
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress GlobeNewswire Inc. - 5/20/2019 7:00:00 AM
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting GlobeNewswire Inc. - 5/16/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2019 4:17:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/10/2019 7:31:17 AM
Stemline Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire Inc. - 5/10/2019 6:30:00 AM
Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019 GlobeNewswire Inc. - 5/8/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 5/2/2019 6:03:32 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/30/2019 5:22:44 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/30/2019 5:20:17 PM
DonShimoda   Tuesday, 06/18/13 05:05:38 PM
Re: DonShimoda post# 1
Post # of 53 
SL-401 receives Orphan Drug designation in BPDCN. A pivotal registration trial is expected to start in early 2014.

NEW YORK, June 10, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (STML) today announced that SL-401 has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic malignancy for which there is no effective treatment. SL-401 also has Orphan Drug status for the treatment of acute myeloid leukemia (AML).

SL-401 is a novel targeted therapy directed to the interleukin-3 receptor (IL-3R) present on tumor bulk and cancer stem cells (CSCs) of multiple hematologic cancer indications. SL-401 has demonstrated single agent clinical activity in patients with advanced hematologic cancers, including BPDCN, AML, and myelodysplastic syndrome (MDS).

"We are focused on the rapid development of SL-401 due to its potential for the treatment of IL-3R-expressing hematologic malignancies," commented Eric K. Rowinsky, M.D., Chief Medical Officer and Head of Research and Development at Stemline. "SL-401 is demonstrating robust clinical activity in heavily-pretreated patients with BPDCN who are refractory to available therapies, including high-dose chemotherapy and allogeneic stem cell transplantation. This Orphan Drug designation provides us with a number of benefits that further strengthen our SL-401 program. Stemline will progress SL-401 into pivotal trials in BPDCN and AML in the near-term, and we will continue to evaluate SL-401 in a wide range of additional IL-3R-expressing hematopoietic malignancies."

About Orphan Drug Designation:
Orphan Drug designation is granted by the FDA's Office of Orphan Products Development for drugs that are expected to provide significant therapeutic advantage over existing treatments and that target conditions affecting 200,000 or fewer U.S. patients annually. Orphan Drug designation qualifies a company for several benefits under the Orphan Drug Act of 1983. The benefits apply across all stages of drug development and include accelerated approval process; seven years of market exclusivity following marketing approval; tax credits on U.S. clinical trials; eligibility for Orphan Drug grants; and waiver of Prescription Drug User Fee Act (PDUFA) and certain other administrative fees.

About Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN):
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic cancer for which there is no effective treatment, carries a poor prognosis and represents an unmet medical need. BPDCN had previous names, including blastic NK cell lymphoma and agranular CD4+/CD56+ hematodermic neoplasm, until 2008 at which time the World Health Organization (WHO) renamed this disease BPDCN. The disease most commonly affects middle-aged and older patients and is approximately three times more common in men than women. BPDCN derives from plasmacytoid dendritic cells, which are specialized cells of the immune system. BPDCN cells express high levels of IL-3R. BPDCN, which has features of both leukemias as well as lymphomas, typically presents with skin lesions, and often also involves the bone marrow and blood, and can also involve the spleen and lymph nodes. BPDCN proliferation in the bone marrow results in decreased blood cell counts, which can lead to serious infections, anemia, bleeding, and invariably death. Although BPDCN can be controlled for brief periods with standard chemotherapy, including high-dose chemotherapy with bone marrow transplantation, overall prognosis remains poor and the median overall survival from diagnosis is approximately 12 months. There are currently no approved therapies for BPDCN, and an optimal therapeutic regimen for BPDCN has not yet been established.

About Stemline:
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Stemline's clinical candidates, SL-401 and SL-701, have demonstrated clinical activity, including durable complete responses (CRs), in Phase 1/2 studies of patients with advanced hematological and brain cancer, respectively. For more information about Stemline Therapeutics, visit www.stemline.com.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist